|
Schirdewan博士的引述的參考文獻: 4 p/ ^6 z5 v: t% v; `: l8 }
: b! o2 a3 k* J) J, Q8 u! CCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. $ W9 t) [5 V F7 P# [" H7 |
% V) V c; c6 H w
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
5 K' q" p+ t1 ?) J }5 `
3 Z: o- f% c3 g/ YRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. ( E' g( A% z N4 @8 M
* g4 w% D3 j6 W+ g2 ^關於BIOTRONIK SE & Co. KG( a+ B7 V9 o. [5 X( X5 `8 v6 ~7 Z* X
$ {7 A4 \; G- V3 p
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|